<DOC>
	<DOCNO>NCT00024271</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving drug directly tumor surgery combining radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine surgery , chemotherapy , radiation therapy treat patient peritoneal cancer .</brief_summary>
	<brief_title>Surgery , Chemotherapy , Radiation Therapy Treating Patients With Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate , duration response , duration survival patient peritoneal mesothelioma treat surgery , intraperitoneal chemotherapy , whole abdominal radiotherapy . - Determine toxicity regimen patient . OUTLINE : Patients undergo initial surgery , include total omentectomy excision gross disease . Approximately 3-4 week surgery , patient receive intraperitoneal ( IP ) chemotherapy consist doxorubicin IP 2 hour weekly week 1 , 4 , 7 , 10 cisplatin IP gemcitabine IP weekly week 2 , 5 , 8 , 11 . Patients also receive interferon gamma IP weekly week 13-16 . At approximately week 18-20 , patient undergo second-look surgery . Patients gross disease receive hyperthermia mitomycin IP cisplatin IP 90 minute . Approximately 2-4 week second-look surgery , patient undergo radiotherapy 5 day week 5-7 week . Treatment continue absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year , every 6 month 3 year , annually 5 year . PROJECTED ACCRUAL : A total 15 patient accrue study .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant mesothelioma Measurable evaluable disease Ineligible highpriority study No CNS metastases PATIENT CHARACTERISTICS : Age : Over 18 Performance status : SWOG 02 Karnofsky 60100 % Life expectancy : More 2 month Hematopoietic : WBC great 3,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 1.5 time normal Renal : Creatinine clearance least 45 mL/min BUN le 1.5 time normal No significant calcium abnormality Cardiovascular : No symptomatic cardiovascular disease No New York Heart Association class II , III , IV heart disease No congestive heart failure No angina pectoris No cardiac arrhythmia No uncontrolled hypertension Other : No significant phosphate , electrolyte , metabolic abnormality ( e.g. , metabolic acidosis ) No uncontrolled psychiatric disorder neurologic disease No seizure disorder No malignancy within past 5 year except curatively treat carcinoma situ cervix skin cancer No serious medical psychiatric illness No uncontrolled serious infection No senility emotional instability Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No 2 prior chemotherapy regimens No 1 prior intraperitoneal chemotherapy regimen More 6 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy except nondiseaserelated condition ( e.g. , insulin diabetes ) Concurrent steroid antiemesis , premedication , adrenal failure , septic shock allow Radiotherapy : No prior abdominal , pelvic , low chest radiotherapy Surgery : Prior surgical resection precede disease recurrence allow More 1 week since prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2004</verification_date>
	<keyword>localize malignant mesothelioma</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
</DOC>